MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication BUFFALO, N.Y., May 5, 2026 — Biotechnology company MimiVax Inc. and Roswell Park Comprehensive Cancer Center today jointly announced the launch of…